IPO
Unicorn Hunters is a new Internet reality show where startup companies can pitch a group of well-known panelists dubbed the “Circle of Money” which allows for a kind of crowdsourced funding appeal.
There were seven initial public offerings (IPOs) for biotech companies in the month of May. Here’s a look.
The company, which isn’t expected to enter the clinic until possibly in 2022, is working to make cell therapies work in solid tumors.
The additional 100 people will be placed in Seattle, San Francisco, and Cambridge, Mass. by the end of the year.
Janux plans to use the funds raised from the IPO to submit four Investigational New Drug applications to the U.S. FDA in the first half of 2022.
Biotechnology firm Ginkgo Bioworks is going public via a merger with Soaring Eagle Acquisition Corp.
With 2020 holding a record number of biotech IPOs, this year is lining up to come close. Three more Bay Area life science companies are just about ready to hit the Nasdaq, adding to the growing list for 2021.
Two weeks after announcing plans for initial public offerings, Gyroscope Therapeutics and Talaris Therapeutics have now set the terms for their debut on the Nasdaq.
After quietly filing plans for an initial public offering earlier this month, U.K.-based Vaccitech raised $110.5 million in its IPO.
Molecular Partners announced yesterday it has filed for a $100 million initial public offering with the Securities and Exchange Commission in the U.S., funding which will go toward supporting the company’s work in the development of protein-based treatments for COVID-19 and various cancers.
PRESS RELEASES